Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Drug-Releasing implant aims to boost hearing for adults with severe loss

NCT ID NCT06424262

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a new cochlear implant that slowly releases dexamethasone, a drug that reduces inflammation after surgery. The goal is to see if it works better than a standard implant for adults with severe hearing loss. About 48 adults will be randomly assigned to get either the new or standard implant and will be followed for 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Jun 2024

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older (at time of consent) * Clinically established post-linguistic bilateral moderately severe to profound sensorineural hearing loss * Meets local candidacy criteria for cochlear implantation * Compromised functional hearing with a hearing aid in the ear to be implanted * Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm * Evidence of pneumococcal vaccination (e.g., Pneumovax) according to local guidelines prior to randomisation * Candidate is proficient in the language used to assess speech perception performance * Willing and able to provide written informed consent. Exclusion Criteria: * Planned for a partial insertion of the electrode array * Intra-axial (within the brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted * Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment * Active autoimmune disease or active immunosuppressive therapy * Any of the following in the ear to be implanted within 3 months prior to enrolment: history of prior otologic surgery including grommets, or tympanic membrane perforation * Previously reported diagnosis of auditory neuropathy, in the ear to be implanted * Previously reported diagnosis, in the ear to be implanted, of Large Vestibular Aqueduct Syndrome (LVAS), Meniere's disease, or cochlear hydrops * Ossification, otosclerosis, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by imaging, in the ear to be implanted * Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, temporo- parietal skull fracture or CSF leaks * History of bacterial meningitis * Known allergic reaction or contraindication to dexamethasone or corticosteroids * Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the subject * Severe, or poorer, sensorineural hearing loss of more than 20 years, as reported by the subject, in the ear to be implanted * Prior cochlear implantation, in either ear * Medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted * Medical or psychological conditions that contraindicate general anaesthesia, surgery or participation in the clinical investigation, as determined by the investigator * Women who are pregnant * Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator * Additional disabilities that may affect the subject's participation or safety during the clinical investigation, as determined by the Investigator * Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator * Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling to the study candidate * Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation * Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by investigator or Sponsor to not impact this investigation) * Subjects recruited at a French site who are not affiliated with social security * Subjects recruited at a French site who are under legal protection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hearing loss, bilateral are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire Toulouse

    Toulouse, France

  • Centre Hospitalier Universitaire de Lille

    Lille, France

  • Hôpital Universitaire Pitié-Salpêtrière

    Paris, France

  • Macquarie University

    Sydney, New South Wales, Australia

  • Manchester Royal Infirmary

    Manchester, United Kingdom

  • Medizinische Hochschule Hannover

    Hanover, Lower Saxony, Germany

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, Australia

  • Royal Victorian Eye and Ear Hospital

    Melbourne E., Victoria, Australia

  • St Vincent Private Hospital

    Melbourne, Victoria, Australia

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Freiburg Im Breisgau, Germany

  • Westmead Private Hospital

    Sydney, New South Wales, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.